Meyka Pro banner
Upexi, Inc.

Upexi, Inc. Fundamental Analysis (NASDAQ: GRVI)

GRVI●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$4.95
$0.35(7.61%)
U.S. Market is Open · 13:17

Upexi, Inc. Fundamental Analysis (NASDAQ: GRVI)

Upexi, Inc. (NASDAQ: GRVI) shows weak financial fundamentals with a PE ratio of -1.28, profit margin of -9.84%, and ROE of -4.51%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.00
Current Ratio1.64

Areas of Concern

ROE-4.51%
Operating Margin-9.63%
Cash Position1.84%
We analyze GRVI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1399.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1399.5/100

We analyze GRVI's fundamental strength across five key dimensions:

Efficiency Score

Weak

GRVI struggles to generate sufficient returns from assets.

ROA > 10%
-1.37%

Valuation Score

Excellent

GRVI trades at attractive valuation levels.

PE < 25
-1.28
PEG Ratio < 2
-0.00

Growth Score

Moderate

GRVI shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

GRVI maintains a strong and stable balance sheet.

Debt/Equity < 1
-4.16
Current Ratio > 1
1.64

Profitability Score

Weak

GRVI struggles to sustain strong margins.

ROE > 15%
-450.66%
Net Margin ≥ 15%
-9.84%
Positive Free Cash Flow
No

Key Financial Metrics

Is GRVI Expensive or Cheap?

P/E Ratio

GRVI trades at -1.28 times earnings. This suggests potential undervaluation.

-1.28

PEG Ratio

When adjusting for growth, GRVI's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Upexi, Inc. at -5.84 times its book value. This may indicate undervaluation.

-5.84

EV/EBITDA

Enterprise value stands at -3.06 times EBITDA. This is generally considered low.

-3.06

How Well Does GRVI Make Money?

Net Profit Margin

For every $100 in sales, Upexi, Inc. keeps $-9.84 as profit after all expenses.

-9.84%

Operating Margin

Core operations generate -9.63 in profit for every $100 in revenue, before interest and taxes.

-9.63%

ROE

Management delivers $-4.51 in profit for every $100 of shareholder equity.

-4.51%

ROA

Upexi, Inc. generates $-1.37 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.37%

Following the Money - Real Cash Generation

Operating Cash Flow

Upexi, Inc. generates limited operating cash flow of $-5.92M, signaling weaker underlying cash strength.

$-5.92M

Free Cash Flow

Upexi, Inc. generates weak or negative free cash flow of $-5.92M, restricting financial flexibility.

$-5.92M

FCF Per Share

Each share generates $-0.33 in free cash annually.

$-0.33

FCF Yield

GRVI converts -23.57% of its market value into free cash.

-23.57%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.28

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-5.84

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.56

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-4.16

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.64

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-4.51

vs 25 benchmark

ROA

Return on assets percentage

-1.37

vs 25 benchmark

ROCE

Return on capital employed

-2.21

vs 25 benchmark

How GRVI Stacks Against Its Sector Peers

MetricGRVI ValueSector AveragePerformance
P/E Ratio-1.2830.76 Better (Cheaper)
ROE-450.66%590.00% Weak
Net Margin-984.34%24130.00% Weak
Debt/Equity-4.160.52 Strong (Low Leverage)
Current Ratio1.645.66 Neutral
ROA-136.61%-172.00% (disorted) Weak

GRVI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Upexi, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ